News
CINGW
0.0220
0.00%
0.0000
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
Cingulate is a biopharmaceutical company utilizing its drug delivery platform technology. Peter Werth will join Cingulate in a live Benzinga All Access event on Friday May 3, 2024, at 12:10 p.m. EST. The event will be held in New York City.
Barchart · 2d ago
Weekly Report: what happened at CINGW last week (0422-0426)?
Weekly Report · 3d ago
Weekly Report: what happened at CINGW last week (0415-0419)?
Weekly Report · 04/22 11:38
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
Cingulate Inc. Will present at the Planet MicroCap Showcase: VEGAS 2024 conference on Wednesday, May 1, 2024. The biopharmaceutical company will use its drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products.
Barchart · 04/16 16:00
Weekly Report: what happened at CINGW last week (0408-0412)?
Weekly Report · 04/15 11:29
Weekly Report: what happened at CINGW last week (0401-0405)?
Weekly Report · 04/08 11:34
CINGULATE INC - CASH WILL SATISFY OUR CAPITAL NEEDS THROUGH LATE IN Q2 OF 2024
Reuters · 04/01 12:00
Weekly Report: what happened at CINGW last week (0325-0329)?
Weekly Report · 04/01 11:31
Weekly Report: what happened at CINGW last week (0318-0322)?
Weekly Report · 03/25 11:34
Cingulate to Participate in Benzinga All Live Access Event
Chairman and CEO Shane Schaffer will participate in a live Benzinga All Access event on March 22, 2024. Cingulate Inc. Is a biopharmaceutical company utilizing its drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products.
Barchart · 03/19 15:45
Weekly Report: what happened at CINGW last week (0311-0315)?
Weekly Report · 03/18 11:32
Weekly Report: what happened at CINGW last week (0304-0308)?
Weekly Report · 03/11 11:28
Cingulate to Attend DCAT Week 2024 in New York City
Cingulate Inc. Will be attending DCAT Week March 18-21, 2024, in Midtown Manhattan. Cingulate is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build a pipeline of next-generation pharmaceutical products.
Barchart · 03/06 05:45
Weekly Report: what happened at CINGW last week (0226-0301)?
Weekly Report · 03/04 11:32
Weekly Report: what happened at CINGW last week (0219-0223)?
Weekly Report · 02/26 11:47
Weekly Report: what happened at CINGW last week (0212-0216)?
Weekly Report · 02/19 11:49
Weekly Report: what happened at CINGW last week (0205-0209)?
Weekly Report · 02/12 11:37
Weekly Report: what happened at CINGW last week (0129-0202)?
Weekly Report · 02/05 11:47
BUZZ-U.S. STOCKS ON THE MOVE-Edwards Lifesciences, Deckers, Regeneron
Futures tracking the S&P 500 pared gains on Friday after a stronger-than-expected jobs report. The top three NYSE percentage gainers premarket were Hamilton Beach Brands, Deckers. Amazon.com up after strong Q4 results. Skechers and Apple are among the top three Nasdaq percentage losers.
Reuters · 02/02 14:17
Weekly Report: what happened at CINGW last week (0122-0126)?
Weekly Report · 01/29 11:33
More
Webull provides a variety of real-time CINGW stock news. You can receive the latest news about Cingulate through multiple platforms. This information may help you make smarter investment decisions.
About CINGW
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.